目的 探討阿立哌唑口崩片聯(lián)合鹽酸度洛西汀腸溶片治療抑郁癥的臨床療效。方法 選取2015年3月-2019年8月天津市安寧醫(yī)院收治的96例抑郁癥患者為研究對(duì)象，所有研究對(duì)象隨機(jī)分為對(duì)照組和治療組，每組各48例。對(duì)照組患者口服鹽酸度洛西汀腸溶片，40~60 mg/d（根據(jù)患者的病情、耐受性調(diào)整藥物劑量），1次/d；治療組患者在對(duì)照組患者治療的基礎(chǔ)上口服阿立哌唑口崩片，5~10 mg/d（根據(jù)患者的病情及耐受性調(diào)整藥物劑量），1次/d。兩組患者均接受8周治療。觀察兩組的臨床療效，比較兩組的睡眠質(zhì)量、HAMD評(píng)分和血清甲狀腺素水平。結(jié)果 治療后，對(duì)照組、治療組的總有效率分別為83.33%、95.83%，兩組患者的臨床療效有顯著差異（P<0.05）。治療后，兩組患者的入睡時(shí)間、S1+S2時(shí)間均顯著縮短，實(shí)際睡眠時(shí)間、REM、S3+S4時(shí)間以及睡眠效率均明顯升高，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者的入睡時(shí)間、S1+S2時(shí)間均明顯短于對(duì)照組，實(shí)際睡眠時(shí)間、REM、S3+S4時(shí)間以及睡眠效率均明顯高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的HAMD評(píng)分均顯著降低（P<0.05），且治療8周后，治療組的HAMD評(píng)分明顯低于對(duì)照組（P<0.05）。治療8周后，對(duì)照組患者甲狀腺素水平顯著高于治療前（P<0.05）；治療4、8周后，治療組患者甲狀腺素水平顯著高于治療前（P<0.05）；且治療8周后，治療組患者的甲狀腺素水平明顯高于對(duì)照組（P<0.05）。結(jié)論 阿立哌唑口崩片聯(lián)合鹽酸度洛西汀腸溶片治療抑郁癥患者的臨床效果顯著，可降低HAMD評(píng)分，改善睡眠質(zhì)量，顯著提高患者的甲狀腺素水平，且安全性較高，值得推廣使用。

Objective To investigate the effect of Aripiprazole Orally Disintegrating Tablets combined with Duloxetine Hydrochloride Enteric-coated Tablets in treatment of depression. Methods Patients (96 cases) with depression in Tianjin Anning Hospital from March 2015 to August 2019 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Duloxetine Hydrochloride Enteric-coated Tablets, 40-60 mg/time (adjusted the dosage according to the patient's condition and tolerance), once daily. Patients in the treatment group were po administered with Aripiprazole Orally Disintegrating Tablets on the basis of the control group, 5-10 mg/time (adjusted the dosage according to the patient's condition and tolerance), once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and sleep quality, HAMD scores, and peripheral blood thyroxine levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 95.83%, respectively, and there was difference between two groups (P<0.05). After treatment, sleep time and S1 + S2 time in two groups were significantly shorted, but actual sleep time, REM, S3 + S4 time, and sleep efficiency in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And sleep time and S1 + S2 time in the treatment group were significantly shorter than those in the control group, but actual sleep time, REM, S3 + S4 time, and sleep efficiency in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, HAMD scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And after treatment for 8 weeks, the HAMD scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment for 8 weeks, the thyroxine level in the control group was significantly increased, and after treatment for 4 and 8 weeks, the thyroxine level in the treatment group was significantly increased, and the difference was statistically significant in the same group (P<0.05). And after treatment for 8 weeks, the thyroxine level in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P<0.05). Conclusion Aripiprazole Orally Disintegrating Tablets combined with Duloxetine Hydrochloride Enteric-coated Tablets has clinical curative effect in treatment of depression, can significantly reduce HAMD scores, improve sleep quality, and improve thyroxine levels, with the safety, which has a certain clinical application.

R971